arrow
M

Matthew R. Broome

University of Birmingham
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High-Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

揭示全球临床高风险精神分裂症个体中的自杀意念与行为:多变量相关因素和阈下精神病症状

2026-09-130
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Mechanisms underpinning flourishing at the interface of humans and other natural entities: an umbrella review

人类与其他自然实体交互界面繁荣发展的基础机制:一项伞式综述

2026-07-290
OAAI
Ecological-collective-flourishing (e-co-flourishing): a framework to guide innovation and research

生态-集体-繁荣(e-co-flourishing):指导创新与研究的框架

2026-07-290
OAAI
Bridging gaps in youth mental health care: YOUTHreach—a comprehensive European strategy

弥合青年心理健康护理的差距:YOUTHreach——一项全面的欧洲战略

2026-04-250
OAAI
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER

一项随机对照试验,旨在评估兴奋剂与非兴奋剂药物对伴有精神病史或双相障碍的成人注意缺陷/多动障碍患者的临床和经济效果:SNAPPER

2025-11-060
OA
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership—Schizophrenia

临床高风险精神病患者的大规模国际样本中,预后调整问题、阴性症状和认知障碍:来自加速药物合作计划—精神分裂症的研究结果

2025-01-010
OA
The effects and costs of an anti-bullying program (KiVa) in UK primary schools: a multicenter cluster randomized controlled trial
2024-11-121
OAAI